Consequently, inhibition of the fatty acid synthase by the anti-obesity drug orlistat, the antibiotic FASN inhibitor cerulenin, and the SCD1 inhibitor CAY10566 resulted in decreased CHIKV and MAYV genome replication (see Figure 3) [99,100]. Here, FASN is linked to obesity disorder.